Sana Biotechnology (SANA) risk factors

Item 1A of every Sana Biotechnology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open SANA in Gloom →

Sana Biotechnology's chart, financials and news, free in your browser.Open SANA in Gloom →

FY2025 10-K risk factors
74 risks2 new1 dropped19 reworded
New risks emphasize GenAI confidentiality and accelerated-approval failure; portfolio changes now prioritize SC451 and fusogen programs while suspending two CAR T programs.
Filed Mar 03, 2026
FY2024 10-K risk factors
73 risks
Sana Biotechnology faces significant clinical and commercial risks centered on cell therapy development, complex biologic manufacturing, and intellectual property protection. The company has undergone multiple workforce reductions and strategic restructurings, including shifting its fusogen platform focus.
Filed Mar 17, 2025